References
- Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial InvestigatorsPlatelet Glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapyN Engl J Med199833974364439705684
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trialLancet200035692472037204411145489
- McClureMWBerkowitzSDSparapaniRClinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experienceCirculation199999222892290010359733
- GaoCBoylanBBougieDEptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domainJ Clin Invest2009119350451119197137
- RussellKNSchnabelJGRochettoRPTannerMCAcute profound thrombocytopenia associated with readministration of eptifibatide: Case report and review of the literaturePharmacotherapy200929786787419558261
- RizviMAKojouriKGeorgeJNDrug-induced thrombocytopenia: An updated systematic reviewAnn Intern Med2001134434611182857
- AsterRHDrug-induced immune thrombocytopenia: An overview of pathogenesisSemin Hematol199936Suppl 1269930556
- DasguptaHBlankenshipJCWoodGCFreyCMDemkoSLMenapaceFJThrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysisAm Heart J2000140220621110925331
- FergusonJJKereiakesDJAdgeyAASafe use of platelet GP IIb/IIIa inhibitorsEur Heart J199819Suppl D40519503175
- MadanMKereiakesDJHermillerJBEfficacy of abciximab readministration in coronary interventionAm J Cardiol200085443544010728946
- VahdatBCanavyIFourcadeLFatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatmentCatheter Cardiovasc Interv200049217718010642768
- TchengJEKereiakesDJLincoffAMAbciximab readministration: Results of the ReoPro Readministration RegistryCirculation2001104887087511514371
- CurtisBRDivgiAGarrittyMAsterRHDelayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drugJ Thromb Haemost20042698599215140135
- CurtisBRSwyersJDivgiAMcFarlandJGAsterRHThrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated plateletsBlood20029962054205911877279
- HongoRHBrentBNAssociation of eptifibatide and acute profound thrombocytopeniaAm J Cardiol200188442843111545770
- BougieDWWilkerPRWuitschickEDAcute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIaBlood200210062071207612200368
- BillheimerJTDickerIBWynnREvidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediatedBlood200299103540354611986205
- AsterRHCurtisBRBougieDWThrombocytopenia associated with the use of GPIIb/IIIa inhibitors: Position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitorsJ Thromb Haemost20064367867916460451
- SaneDCDamarajuLVTopolEJOccurrence and clinical significance of pseudothrombocytopenia during abciximab therapyJ Am Coll Cardiol2000361758310898416
- WarkentinTEGreinacherAHeparin-induced thrombocytopenia: Recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126Suppl 3311S337S15383477
- BennettCLConnorsJMCarwileJMThrombotic thrombocytopenic purpura associated with clopidogrelN Engl J Med2000342241773177710852999
- NaranjoCABustoUSellersEMA method for estimating the probability of adverse drug reactionsClin Pharmacol Ther19813022392457249508